arrow
C

C. Paul

department of dermatology
H指数:90
被引数:2.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials

德卡鲁昔替尼治疗斑块状银屑病5年安全性和有效性结果:一项随机临床试验的III期开放标签扩展研究

2026-08-070
OA
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

更正:来自ALLEGRO临床研究项目的口服JAK3/TEC家族激酶抑制剂Ritlecitinib治疗斑秃的综合安全性分析

2025-09-110
OAAI
Impact of methotrexate administration route on drug survival in psoriasis: Results from PSOBIOTEQ

甲氨蝶呤给药途径对银屑病患者药物生存期的影响:PSOBIOTEQ研究的结果

2025-09-010
PRE
Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme

在ALLEGRO临床开发计划中,接受利特昔替尼治疗斑秃患者的临床反应模式

2025-02-171
OAAI
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis The OLYMPIA 1 Randomized Clinical Phase 3 Trial

中重度结节性痒疹患者中Nemolizumab的疗效与安全性:OLYMPIA 1随机临床试验(III期)

2025-02-014
PRE
Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseases
2024-12-180
OAAI
Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis
2024-09-014
OAAI
Superficial Conjunctival Cells from Dupilumab-Treated Patients with Atopic Dermatitis with Ocular Adverse Events Display a Transcriptomic Psoriasis Signature

特应性皮炎伴眼部不良事件且接受度普利尤单抗治疗患者的浅层结膜细胞显示出转录组学银屑病特征

2024-09-010
OAAI
Gain-of-function human UNC93B1 variants cause systemic lupus erythematosus and chilblain lupus
2024-06-1310
OAAI
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program (vol 25, pg 299, 2024)
2024-05-240
OAAI